Italy was the first western country to be overwhelmed by COVID-19, which was declared a pandemic by the World Health Organization on 11 March 2020.1 Many papers have been published since then, and they have provided valuable information on the pathophysiology, prognosis and treatment strategies for COVID-19. However, data on paediatric patients are still lacking and the material that is available tends to be confusing.2,3 Children under 10 years of age represent less than 1% of all COVID-19 cases and appear to be affected more mildly than adults and show a more favourable clinical course. Children under 5 years of age, particularly those under 1 year of age and those with pre-existing comorbidities, could be more vulnerable to having moderate-to-severe COVID-19 disease, as reported by recent papers.4–8 Furthermore, it has been suggested that very young age could be a potential risk factor for community-acquired severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We retrospectively enrolled 39 infants up to 6 months of age who had presented to our tertiary Italian children’s hospital emergency room between 9 March 2020 and 8 March 2021 and tested positive for the virus. Of those, 38 had a non-specific mild or asymptomatic clinical course and only one patient was admitted to intensive care with severe symptoms. We concluded that very young infants with COVID-19 had a generally favourable disease course.

**Keywords**
asymptomatic, disease course, emergency room, infants, pandemic

The main limitations of COVID-19 paediatric studies have been that they have covered patients from 0 to 18 years of age.5,6,14 Only a few papers have split patients into different age groups, such as less than 1 year of age, 1–9 years and 9–18 years.13–15

The aim of this paper was to report data on infants up to 6 months of age who were admitted to the emergency department (ED) of the Gianna Gaslini Children, in Genoa, Italy, with a confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We wanted to assess whether this age group represented a risk factor for moderate-to-severe COVID-19 disease.

This 1-year study took place from 9 March 2020, which was the first day of the Italian lockdown, to 8 March 2021. Nasopharyngeal swabs and real-time polymerase chain reaction tests were used to detect SARS-CoV-2. A flow chart of the inclusion and exclusion criteria is presented in Figure 1.
If the patients tested positive for the virus, we recorded their age and perinatal and family history. The clinical data that were recorded were their symptoms, blood examination result on admission and after 36–48 h of hospitalisation, radiological tests and any therapies administered.

We found that 20,091 patients presented to our ED during the 1-year study period. Of the 205 who tested positive for the SARS-CoV-2 virus, 39 (19%) were up to 6 months of age, with a median age of 79 days (range 9–210), and 64% of those were male. More than half, 23/39 (59%), were less than 3 months old, including three (8%) under 28 days of age, and 16 (41%) who were at least 3 months old. None had been born preterm. We noted that 15 (38%) had an older sibling and 36 (92%) had at least one parent who also has been old. None had been born preterm. We noted that 15 (38%) had an age of 79 days (range 9–210), and 64% of those were male. More than half, 23/39 (59%), were less than 3 months old, including three (8%) under 28 days of age, and 16 (41%) who were at least 3 months old. None had been born preterm.

Children under the age of 6 months who presented to an ED and tested positive for the SARS-CoV-2 virus over a 1-year period. Previous studies limited their investigations to smaller samples of patients with the virus or limited their diagnostic assessments were deemed necessary.

We gave six (15%) patients antibiotic therapy, due to suspected bacterial co-infection, and there were three (8%) who required supportive intravenous fluids. Most of the patients, 32/39 (82%), received symptomatic therapy or did not require any care.

Laboratory tests revealed neutropenia in three patients, and in two cases their absolute neutrophil count normalised after 36–48 h. Conversely, three patients who had normal levels when they presented to the ED had developed neutropenia at 36–48 h. Slight lymphopenia was detected in two infants during their ED evaluation, but they did not include the infant with the history of pancytopenia.

With the exception of the patient with sepsis-like syndrome, none of the patients who were tested for biomarkers, namely C-reactive protein and procalcitonin, presented with elevated inflammation.

A total of 28 patients (72%) were hospitalised for a median of 5 days (range 2–60), including all three neonates. None of the patients were rehospitalised within 72 h of being discharged or developed childhood multisystem inflammatory syndrome associated with COVID-19 when they were followed up for at least 2 months.

We believe that this was the biggest study to focus on infants under the age of 6 months who presented to an ED and tested positive for the SARS-CoV-2 virus over a 1-year period. Previous studies looked at smaller samples of patients with the virus or limited their studies to patients under 60 days of age.

The lack of information on COVID-19 characteristics in vulnerable patients up to 6 months of age continues to challenge ED physicians, but our data suggest that these infants experienced non-specific milder or asymptomatic forms of COVID-19. In addition, the normal values of C-reactive protein, procalcitonin and absolute neutrophil count were consistent with a mild inflammatory response. Virtually, all of our patients presented with mild or no symptoms, including those with comorbidities and those with a remarkable perinatal history.

As stated above, only one child became severely ill after developing COVID-19. He needed to be admitted to the intensive care unit and was treated with mechanical ventilation, probably due to the fact that he had pancytopenia and suspected immunodeficiency. He then developed central venous catheter-related sepsis caused by *Methicillin-susceptible staphylococcus aureus*.

With the exception of that 4-month-old boy, none of our other patients presented with the severe underlying conditions that have been associated with a higher risk of severe COVID-19. These include severe congenital heart disease, genetic, metabolic and, or, neurological diseases, which have been associated with a higher risk of severe COVID-19.
Other clinical conditions known to increase the risk of severe COVID-19, such as asthma, diabetes, obesity and hypertension, are uncommon in very young patients and were absent in this cohort.

Our study had some limitations, including the fact that retrospective designs can introduce bias. Although this study was one of the largest COVID-19 series to be carried out on patients under the age of 6 months, we are still confident that children of that age are a fairly small percentage of those afflicted by the disease.8,10,11,15

We believe that our study provides valuable insights into the clinical and biochemical characteristics of infants under the age of 6 months who are infected with SARS-CoV-2. Our findings suggest that this age group was relatively spared from moderate-to-severe COVID-19 and presented with a favourable course. The experiences of young infants who develop COVID-19 are still evolving, and most of the knowledge that is available comes from anecdotal reports. That is why more prospective studies are needed. As shown in Figure 2, our experience demonstrated that infants with COVID-19 did not present with a specific clinical picture, but the clinical course was generally favourable.

CONFLICT OF INTEREST
The authors have no conflicts of interest to declare.

REFERENCES
1. Venturini E, Montagnani C, Garazzino S, et al. Treatment of children with COVID-19: position paper of the Italian Society of Pediatric Infectious Disease. Ital J Pediatr. 2020;46(1):139.
2. Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242.
3. Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782-793.
4. CDC COVID-19 Response Team. Coronavirus disease 2019 in Children—United States, February 12–April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(14):422-426.
5. Brisca G, Mariani M, Andrea Rotulo G, et al. Clinical course of COVID-19 in children with pre-existing medical conditions. Acta Paediatr. 2021;110(4):1291-1292.
6. Yashara J, Kuno T, Takagi H, et al. Clinical characteristics of COVID-19 in children: a systematic review. Pediatr Pulmonol. 2020;55(10):2565-2575.
7. Nathan N, Prevost B, Corvol H. Atypical presentation of COVID-19 in young infants. Lancet. 2020;395(10235):1481.
8. Kloc M, Ghobrial RM, Kuchar E, et al. Development of child immunity in the context of COVID-19 pandemic. Clin Immunol. 2020;217:108510.
9. Simon AK, Hollander GA, McMichael A. Evolution of the immune system from infancy to old age. Proc Biol Sci. 2015;282(1821):20143085.
10. Hassan M, Khalil A, Magboul S, et al. Neonates and young infants with COVID-19 presented with sepsis-like syndrome: a retrospective case controlled study. Front Pediatr. 2021;9:634844.
11. Zhou B, Yuan Y, Wang S, et al. Risk profiles of severe illness in children with COVID-19: a meta-analysis of individual patients. Pediatr Res. 2021;90:1-6.
12. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020;145(6):e20200702.
13. Spoulou V, Noni M, Koupou D, et al. Clinical characteristics of COVID-19 in neonates and young infants. Eur J Pediatr. 2021;180:1-5.
14. Li J, Thoon KC, Chong CY, et al. Comparative analysis of symptomatic and asymptomatic SARS-CoV-2 infection in children. Ann Acad Med Singap. 2020;49(8):530-537.
15. Hassoun A, Dahan N, Kelly C. A case series of SARS-CoV-2 RT-PCR-positive hospitalized infants 60 days of age or younger from 2 New York City pediatric emergency departments. Clin Pediatr (Phila). 2021;60(4-5):247-251.
16. Cattalini M, Taddio A, Bracaglia C, et al. Childhood multisystem inflammatory syndrome associated with COVID-19 (MIS-C): a diagnostic and treatment guidance from the Rheumatology Study Group of the Italian Society of Pediatrics. Ital J Pediatr. 2021;47(1):24.

How to cite this article: Bellini T, Rotulo GA, Caruggi S, Carta S, Bonato I, Piccotti E. Characteristics of COVID-19 patients up to 6 months of age admitted to a paediatric emergency department. Acta Paediatr. 2022;111:272–274. https://doi.org/10.1111/apa.16166